The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Claim CLM-00001. 1. A method of treating a human suffering from Fragile X Syndrome comprising: administering 250 mg or 500 mg of synthetic or purified cannabidiol in a pharmaceutically acceptable carrier to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.